JF
BCLI

Jump Financial’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Jump Financial’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-733
Closed -$2.53K – 1646
2024
Q3 		$2.53K Buy
+733
New +$3.46K ﹤0.01% 1576
2020
Q4 		– Sell
-733
Closed -$186K – 950
2020
Q3 		$186K Buy
+733
New +$150K 0.04% 642

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jump Financial's BCLI Position: Q4 2024 in Review

Jump Financial sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 733 shares — an estimated $2.53K sold.

Jump Financial first reported a position in BCLI in Q3 2020 and held it in 2 quarters. The position peaked at $186K in Q3 2020. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Jump Financial reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Jump Financial sold 733 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $2.53K.
  • Jump Financial first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2020 and held it in 2 quarters.
  • Jump Financial's BRAINSTORM CELL THERAPUTC position peaked at $186K in Q3 2020.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Jump Financial's 13F filing for Q4 2024, filed 13 Feb 2025.